Comprehensive gene expression analysis detects global reduction of proteasome subunits in schizophrenia
暂无分享,去创建一个
Eytan Domany | Mark Weiser | Nicola Maggio | Assif Yitzhaky | Libi Hertzberg | Vahram Haroutunian | E. Domany | V. Haroutunian | P. Katsel | Assif Yitzhaky | M. Weiser | L. Hertzberg | N. Maggio | Pavel Katsel | Inna Muler | Michael Majer | Inna Muler | Michael Majer
[1] Stephen J Glatt,et al. Preliminary evidence of ubiquitin proteasome system dysregulation in schizophrenia and bipolar disorder: Convergent pathway analysis findings from two independent samples , 2010, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.
[2] Christos Pantelis,et al. Age of onset of schizophrenia: perspectives from structural neuroimaging studies. , 2011, Schizophrenia bulletin.
[3] C. Ross,et al. Increased Protein Insolubility in Brains From a Subset of Patients With Schizophrenia. , 2019, The American journal of psychiatry.
[4] K. Davis,et al. Large-scale microarray studies of gene expression in multiple regions of the brain in schizophrenia and Alzheimer's disease. , 2005, International review of neurobiology.
[5] C. Tamminga,et al. F168. Increased Protein Insolubility in Brains From a Subset of Patients With Schizophrenia , 2019, Biological Psychiatry.
[6] Davide Heller,et al. STRING v10: protein–protein interaction networks, integrated over the tree of life , 2014, Nucleic Acids Res..
[7] E. Kemether,et al. Thalamic transcriptome screening in three psychiatric states , 2009, Journal of Human Genetics.
[8] V. Haroutunian,et al. Dysfunction of the Ubiquitin Proteasome and Ubiquitin-Like Systems in Schizophrenia , 2013, Neuropsychopharmacology.
[9] V. Haroutunian,et al. Variations in differential gene expression patterns across multiple brain regions in schizophrenia , 2005, Schizophrenia Research.
[10] V. Haroutunian,et al. Protein Expression of Proteasome Subunits in Elderly Patients with Schizophrenia , 2016, Neuropsychopharmacology.
[11] J. Pierri,et al. Gene Expression Profiling Reveals Alterations of Specific Metabolic Pathways in Schizophrenia , 2002, The Journal of Neuroscience.
[12] S. Faraone,et al. Genes, environment and schizophrenia. , 2001, The British journal of psychiatry. Supplement.
[13] M. Tsuang,et al. Positive symptoms of psychosis correlate with expression of ubiquitin proteasome genes in peripheral blood , 2010, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.
[14] R. Granger,et al. DLPFC Transcriptome Defines Two Molecular Subtypes of Schizophrenia , 2017, bioRxiv.
[15] Damian Szklarczyk,et al. The STRING database in 2017: quality-controlled protein–protein association networks, made broadly accessible , 2016, Nucleic Acids Res..
[16] Ben-Ari FuchsShani,et al. GeneAnalytics: An Integrative Gene Set Analysis Tool for Next Generation Sequencing, RNAseq and Microarray Data , 2016 .
[17] Terry M. Therneau,et al. Faster cyclic loess: normalizing RNA arrays via linear models , 2004, Bioinform..
[18] J. T. Webster,et al. The Use of an F-Statistic in Stepwise Regression Procedures , 1972 .
[19] W H Wong,et al. Genome-wide expression analysis reveals dysregulation of myelination-related genes in chronic schizophrenia , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[20] Elijah F. W. Bowen,et al. DLPFC transcriptome defines two molecular subtypes of schizophrenia , 2019, Translational Psychiatry.
[21] W. Markesbery,et al. Decreased levels of proteasome activity and proteasome expression in aging spinal cord , 2000, Neuroscience.
[22] Aiqing He,et al. Distinctive transcriptome alterations of prefrontal pyramidal neurons in schizophrenia and schizoaffective disorder , 2014, Molecular Psychiatry.
[23] Andrew L. Lemire,et al. Deficient Hippocampal Neuron Expression of Proteasome, Ubiquitin, and Mitochondrial Genes in Multiple Schizophrenia Cohorts , 2005, Biological Psychiatry.
[24] G. Godefroy,et al. Voronoi tessellation to study the numerical density and the spatial distribution of neurones , 2000, Journal of Chemical Neuroanatomy.
[25] R. Yolken,et al. The Stanley Foundation brain collection and Neuropathology Consortium , 2000, Schizophrenia Research.
[26] A. Rademaker,et al. A phase II trial evaluating the effects and intra-tumoral penetration of bortezomib in patients with recurrent malignant gliomas , 2016, Journal of Neuro-Oncology.
[27] Dan Tsafrir,et al. Sorting points into neighborhoods (SPIN): data analysis and visualization by ordering distance matrices , 2005, Bioinform..
[28] Kevin P. White,et al. The transcription factor POU3F2 regulates a gene coexpression network in brain tissue from patients with psychiatric disorders , 2018, Science Translational Medicine.
[29] J. Meador-Woodruff,et al. Intracellular compartment-specific proteasome dysfunction in postmortem cortex in schizophrenia subjects , 2019, Molecular Psychiatry.
[30] E. Morrow,et al. Distribution of disease-associated copy number variants across distinct disorders of cognitive development. , 2013, Journal of the American Academy of Child and Adolescent Psychiatry.
[31] M. Barnes,et al. Analysis of gene expression in two large schizophrenia cohorts identifies multiple changes associated with nerve terminal function , 2009, Molecular Psychiatry.
[32] H. Fine,et al. A phase II trial of tamoxifen and bortezomib in patients with recurrent malignant gliomas , 2015, Journal of Neuro-Oncology.
[33] C. Pantelis,et al. Elevated ubiquitinated proteins in brain and blood of individuals with schizophrenia , 2019, Scientific Reports.
[34] Benjamin A. Logsdon,et al. Gene Expression Elucidates Functional Impact of Polygenic Risk for Schizophrenia , 2016, Nature Neuroscience.
[35] Stanley J. Watson,et al. Post-mortem molecular profiling of three psychiatric disorders , 2016, Genome Medicine.
[36] M. Webster,et al. Application of cDNA microarrays to examine gene expression differences in schizophrenia , 2001, Brain Research Bulletin.
[37] C. Davies,et al. Transcription and pathway analysis of the superior temporal cortex and anterior prefrontal cortex in schizophrenia , 2011, Journal of neuroscience research.
[38] H. Friedman,et al. Phase II clinical trial of bortezomib and bevacizumab combination in recurrent glioblastoma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[39] H. Hakonarson,et al. Common and Rare Genetic Risk Factors Converge in Protein Interaction Networks Underlying Schizophrenia , 2018, Front. Genet..
[40] Y. Benjamini,et al. Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .